生物制药公司Arvinas(ARVN.US)今日盘中股价大涨5.09%,引起了市场广泛关注。
消息面上,高盛分析师下调了Arvinas目标股价,由63美元调整至51美元,但维持该公司的买入评级。这或许是导致该股盘中大涨的主要原因。
分析师下调股价目标通常会令公司股价面临一定压力。但在此次情况下,分析师维持了买入评级,或许体现出对公司长期前景的乐观评估,缓解了股价下跌的顾虑,反而引发了投资者的积极买盘。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.